Author

Irena Corbic Ramljak

Observed names: Irena Corbic, Irena Corbic-Ramljak, Irena Čorbic Ramljak, Irena Čorbic-Ramljak, Irena Čorbić Ramljak

Institution: Valneva (Austria)

Observed institutions: Sinovac Biotech, Max Perutz Labs, China National Pharmaceutical Group Corporation (China), Bharat Biotech (India), Vienna Biocenter, Valneva (Austria), University Hospitals Bristol and Weston NHS Foundation Trust, Medical University of Vienna

ORCID: 0000-0002-1127-7123

Observed ORCID: 0000-0002-1127-7123

OpenAlex ID: A5038625321

Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial

2020 · Nina Wressnigg, Romana Hochreiter, et al. · The Lancet Infectious Diseases · 111

Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera

2022 · Pierre Roques, Andrea Fritzer, et al. · JCI Insight · 85

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

2022 · Rajeka Lazarus, Benedicte Querton, et al. · The Lancet Infectious Diseases · 51

Cellular N-myristoyltransferases play a crucial picornavirus genus-specific role in viral assembly, virion maturation, and infectivity

2018 · Irena Corbic Ramljak, Julia Stanger, et al. · PLoS Pathogens · 44

Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults

2022 · Rajeka Lazarus, Christian Taucher, et al. · Journal of Infection · 22

Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial

2023 · Christian Taucher, Rajeka Lazarus, et al. · Journal of Infection · 17

A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine

2022 · Nina V Wressnigg, Romana Hochreiter, et al. · Journal of Travel Medicine · 12

Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial

2021 · Rajeka Lazarus, Christian Taucher, et al. · medRxiv · 12

Pivotal Immune-Bridging Study of the Inactivated Whole-Virus COVID-19 Vaccine VLA2001: A Phase 3, Randomized Controlled Clinical Trial in Adults Using Adenoviral Vector Vaccine AZD1222 as a Comparator

2022 · Rajeka Lazarus, Benedicte Querton, et al. · SSRN Electronic Journal · 1

Works count: 9

Citation count: 355

H-index: 8

I10-index: 8